Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.77 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468600 | 0.92 | ADRA1D (0.72) | ADRA1DSLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7259157 | 0.91 | ADRA1D (0.90) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL14306777 | 0.89 | ADRA1D (0.80) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL11039326 | 0.87 | ADRA1D (0.77) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL5705230 | 0.87 | SLC6A4 (0.90) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL4475225 | 0.86 | ADRA1D (0.67) | ADRA1DSLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7255562 | 0.86 | ADRA1D (1.00) | ADRA1DSLC6A4 | |
| SCHEMBL7260934 | 0.86 | ADRA1D (1.00) | ADRA1DSLC6A4 | |
| SCHEMBL3380974 | 0.86 | SLC6A4 (0.97) | ADRA1DSLC6A4CYP2D6 | |
| SCHEMBL27467624 | 0.86 | ADRA1D (0.77) | ADRA1DSLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | claimed |
| EP-1891068-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | claimed |
| WO-2006138695-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | ADRA1D 11/4885SLC6A4 1123/4885CYP2D6 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.